Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 9, 2014, Pages 1035-1043

  Deepak, P ^a   Stobaugh, D J ^b  

^a MAYO CLINIC   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABORTION; ADVERSE DRUG REACTION; ARTICLE; BLEEDING; CHORIOAMNIONITIS; COMORBIDITY; CONGENITAL MALFORMATION; CONTROLLED STUDY; CROHN DISEASE; DELIVERY; DRUG INDICATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECTOPIC PREGNANCY; FEMALE; FETOTOXICITY; FETUS; FETUS DEATH; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; HUMAN; INFLAMMATORY BOWEL DISEASE; INTRAUTERINE GROWTH RETARDATION; LABOR; LABOR COMPLICATION; LOGISTIC REGRESSION ANALYSIS; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MONOTHERAPY; NEWBORN; NEWBORN DEATH; PLACENTA DISORDER; PREGNANCY; PREGNANT WOMAN; PREMATURE LABOR; PREMATURITY; PRENATAL DRUG EXPOSURE; PUERPERIUM; RISK REDUCTION; ULCERATIVE COLITIS; UTERUS DISEASE; UTERUS RUPTURE; ADULT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FETOMATERNAL TRANSFUSION; INFLAMMATORY BOWEL DISEASES; PREGNANCY COMPLICATIONS; UNITED STATES; YOUNG ADULT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; MATERNAL-FETAL EXCHANGE; POLYETHYLENE GLYCOLS; PREGNANCY; PREGNANCY COMPLICATIONS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84907981212     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12936     Document Type: Article

References (28)

1. Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut 2006; 55: 1198-206.
2. Morales M, Berney T, Jenny A, Morel P, Extermann P. Crohn's disease as a risk factor for the outcome of pregnancy. Hepatogastroenterology 2000; 47: 1595-8.
3. Nielsen OH, Andreasson B, Bondesen S, Jarnum S. Pregnancy in ulcerative colitis. Scand J Gastroenterol 1983; 18: 735-42.
4. Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 2004; 15: 237-41.
5. Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol 1989; 160: 998-1001.
6. Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106: 214-23.
7. Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol 2013; 9: 161-73.
8. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving IFX for the treatment of Crohn0 s disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-92.
9. Casanova MJ, Chaparro M, Doménech E, et al. Safety of thiopurines and anti- TNF-a drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 433-40.
10. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17: 1846-54.
11. Mahadevan U, Martin C, Sandler RS, et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012; 142: S149.
12. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4(5): 621-30.
13. Johnson DL, Jones KL, Chambers CD, Salas E. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology 2009; 136: A-27.
14. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-92.
15. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 228-33.
16. Cleary BJ, Källén B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009; 85: 647-54.
17. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60: 198-203.
18. Food and Drug Administration Adverse Event Reporting System (FAERS) data files. Available at: http://www.fda.gov/Drugs/GuidanceCompliance RegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm. Accessed July 2013.
19. Casson IF, Clarke CA, Howard CV, et al. Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study. BMJ 1997; 315: 275-8.
20. Jacobson JL, Jacobson SW, Sokol RJ, Martier SS, Ager JW, Shankaran S. Effects of alcohol use, smoking, and illicit drug use on fetal growth in black infants. J Pediatr 1994; 124(5 Pt 1): 757-64.
21. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 2013; 93: 539-46.
22. Stobaugh DJ, Deepak P, Ehrenpreis ED. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. J Am Acad Dermatol 2013; 69: 393-8.
23. Lichtenstein GR, Feagan BG, Cohen RD, et al. Pregnancy outcomes in patients with Crohn's disease treated with Infliximab: results from the TREATTM Registry. Am J Gastroenterol 2013; 108(S1): S521.
24. Ban L, Tata LJ, Fiaschi L, Card T. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology 2014; 146: 76-84.
25. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36: 635-41.
26. Gale EA. Collateral damage: the conundrum of drug safety. Diabetologia 2009; 52: 1975-82.
27. Gisbert JP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breastfeeding. Inflamm Bowel Dis 2010; 16: 881-95.
28. Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther 2012; 35: 501-15.